Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers

NCT05428150 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: Esbriet 267 MG Oral Capsule
DRUG: EXCL-100, 600 MG Oral Tablet

Sponsor

Excalibur Pharmaceuticals, Inc.